You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017

The prize is awarded to the companies that made the best use of the capital markets

read more 

CORPORATE

Kedrion Biopharma joins Columbia University to celebrate 50 years of Anti-D

Since 1968, billions of babies have been saved from Hemolytic Disease of the Fetus and Newborn

read more 

CORPORATE

Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

Goal is to improve access to replacement therapies for coagulation disorders in Europe

read more 
  1. EVENTS - 13-07-2015

    Revolutionary PID testing from Tuscany, Italy

    Kedrion at Meyer Hospital’s side to promote early diagnosis of primary immunodeficiencies

    read more 
  2. CORPORATE - 29-06-2015

    Humanitarian programme to reduce the gap in the access to clotting factors

    Kedrion helps the WISH project come true: Italian CNS and the World Federation of Hemophilia sign agreement in London

    read more 
  3. EVENTS - 15-05-2015

    Kedrion Continues Global Expansion with Dedication Ceremony at US Facility

    Biopharma Company Celebrates with Local Guests and Dignitaries in Melville, New York

    read more 
  4. CORPORATE - 30-04-2015

    Kedrion SpA’s Shareholders approve 2014 financial statement

    A 466 million euros’ turnover with a 9,8% rise on 2013

    read more 

Pages

For more information please contact: pressoffice@kedrion.com